E-ISSN 2149-388X | ISSN 2149-0430
 
2026, Vol: 12, Issue: 1
12 / 1Current Issue Online FirstArchiveAims and ScopeAbstracting & IndexingMost Accessed ArticlesMost Downloaded ArticlesMost Cited Articles
Required files to be uploaded

Cover Letter
License Agreement
Title Page

Short Communication 


Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial

Elfreda Dzukey, Kevan English.


Abstract
Antithrombotic treatment in patients with stable coronary artery disease and previous stent implantation who require long-term oral anticoagulation is a constant challenge in clinical practice, especially for patients who are at high risk for vascular and coronary events. Stopping aspirin in high-risk patients with chronic coronary syndrome after percutaneous coronary intervention may lead to recurrent ischemic events, whereas combination therapy with aspirin and oral anticoagulation may lead to a higher risk of bleeding. For decades, we thought the answer of combination therapy was superior to anticoagulation monotherapy. However, several clinical trials have shown evidence against this practice. This short communication provides an in-depth analysis of the AQUATIC clinical trial and its potential implications for the treatment of AF and CAD.

Key words: Chronic coronary syndrome; Aspirin; Direct oral anticoagulants; Clinical trial; Coronary artery disease; Percutaneous coronary intervention; Warfarin


 
ARTICLE TOOLS
Abstract
PDF Fulltext
How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Elfreda Dzukey
Articles by Kevan English
on Google
on Google Scholar


How to Cite this Article
Pubmed Style

Dzukey E, English K. Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial. Ulutas Med J. 2026; 12(1): 4-6. doi:10.5455/umj.20260104053745

Web Style

Dzukey E, English K. Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial. https://www.ulutasmedicaljournal.com/?mno=305478 [Access: March 26, 2026]. doi:10.5455/umj.20260104053745

AMA (American Medical Association) Style

Dzukey E, English K. Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial. Ulutas Med J. 2026; 12(1): 4-6. doi:10.5455/umj.20260104053745


Vancouver/ICMJE Style

Dzukey E, English K. Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial. Ulutas Med J. (2026), [cited March 26, 2026]; 12(1): 4-6. doi:10.5455/umj.20260104053745


Harvard Style

Dzukey, E. & English, . K. (2026) Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial. Ulutas Med J, 12 (1), 4-6. doi:10.5455/umj.20260104053745


Turabian Style

Dzukey, Elfreda, and Kevan English. 2026. Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial. THE ULUTAS MEDICAL JOURNAL, 12 (1), 4-6. doi:10.5455/umj.20260104053745


Chicago Style

Dzukey, Elfreda, and Kevan English. "Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial." THE ULUTAS MEDICAL JOURNAL 12 (2026), 4-6. doi:10.5455/umj.20260104053745


MLA (The Modern Language Association) Style

Dzukey, Elfreda, and Kevan English. "Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial." THE ULUTAS MEDICAL JOURNAL 12.1 (2026), 4-6. Print. doi:10.5455/umj.20260104053745


APA (American Psychological Association) Style

Dzukey, E. & English, . K. (2026) Aspirin Plus Oral Anticoagulation in High-Risk Patients with Stable Coronary Artery Disease After Percutaneous Coronary Intervention Stenting: Important Lessons Learned from the AQUATIC Trial. THE ULUTAS MEDICAL JOURNAL, 12 (1), 4-6. doi:10.5455/umj.20260104053745


Author LoginReviewer LoginAbout PublisherOpen Access PolicyEditorial PoliciesEditorial Review PolicyPeer Review PolicyEditorial & Peer Review ProcessAuthor's Rights and ObligationsPublication Ethics and Publication Malpractice StatementConflict of Interest PolicyPlagiarism PolicyProtection of Research Participants (Statement On Human And Animal Rights)Privacy PolicyCorrections, Retractions & Expressions of ConcernSelf-Archiving PoliciesDigital Archiving & Preservation PoliciesStatement of Informed ConsentAdvertising PolicyTerms of UseLicense InformationCopyright Information

About THE ULUTAS MEDICAL JOURNAL

The Ulutas Medical Journal (UMJ) is a 3 monthly (quarterly), open access, double-blind peer-reviewed, an international journal. Writing a research pap ... Read more.



For best results, please use Internet Explorer or Google Chrome.

Contact Information


Journal Owner
HAYRİYE ZEHRA ULUTAŞ
Phone: +90 (532) 165 96 39​
E-mail: zehrakenanoglu@hotmail.com​
Address: Alaattin Mah. 30. Ada sok. D11 Blok
No:4 Gungor Uydukent Sitesi  Antakya/HATAY

Editor-In-Chief
KEMAL TURKER ULUTAS, MD, Assc. Prof.
Phone: + 90 (555) 491 35 59​
E-mail: drkemalturker@gmail.com
Address: Alaattin Mah. 30. Ada sok. D11 Blok
No:4 Gungor Uydukent Sitesi  Antakya/HATAY

Publisher Information
SCOPEMED Publishing Co. - TURKEY​
E-mail: scopemed@scopemed.org
Web: https://www.scopemed.com/

 

We welcome your submissions, suggestions, comments, or questions. To reach us, please use one of the methods provided on this page or Email us at ulutasmedicaljournal@gmail.com​

We will respond within 48 to 72 hours.